On the 20th, Boryung Pharmaceutical announced that the Ministry of Food and Drug Safety has approved the Phase III clinical trial plan (investigational new drug, IND) for ‘BR1018,’ its incrementally modified drug candidate for hypertension and dyslipidemia.

BR1018 is a four-drug combination that combined amlodipine, atorvastatin, and ezetimibe with fimasartan. Fimasartan is the main active ingredient of Kanarb, a new hypertension drug developed by Boryung. Kanarb was released in 2011 as a new drug for high blood pressure in the angiotensin II receptor blocker (ARB) class and was developed by Boryung with its proprietary technology. Amlodipine is a calcium channel blocker (CCB) type hypertensio